Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential role of psychedelic-assisted therapies in the treatment of (a) treatment-resistant depression, (b) PTSD and (c) other mental health conditions; and what steps his Department is taking to support clinical research into those therapies.

The Department of Health and Social Care is working closely with the Home Office and other key stakeholders across Government to take forward relevant recommendations of the Advisory Council on the Misuse of Drugs’ report on barriers to research involving Schedule 1 controlled drugs, which include substances used in some psychedelic-assisted therapies.

The Department of Health and Social Care also funds research through the National Institute for Health and Care Research, including the Psilocybin in Depression Resistant to Standard Treatments trial, which published its results in August 2026.